当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Vaccination for control of Salmonella in poultry.

Vaccination for control of Salmonella in poultry.

Abstract：

:Salmonella spp. are facultative intracellular pathogens causing localised or systemic infections, in addition to a chronic asymptomatic carrier state. They are of worldwide economic and public health significance. In poultry, which represent important sources of cheap protein throughout the world, fowl typhoid and pullorum disease continue to cause economic losses in those parts of the world where the poultry industries are continuing to intensify and where open sided housing is common. A number of serotypes that cause human gastro-enteritis are also increasing. The costs or impracticality of improvements in hygiene and management together with the increasing problems of antibiotic resistance suggest that vaccination in poultry will become more attractive as an adjunct to existing control measures. However, our understandings of the immunology of Salmonella infections in poultry is rudimentary and much poorer than that of equivalent infections in mice and live vaccine development for poultry has therefore been largely empirical. In addition to the killed Salmonella vaccines which have been used over the past few years with variable efficacy, a number of live vaccines have become available and some new vaccines will appear on the market over the next few years. These new vaccines should fulfil the criteria of efficacy, safety and compatibility with existing systems for monitoring infection before they are released on to a mass market. In this review we attempt to summarise the current understanding of Salmonella immunology in poultry together with the progress that has been made in poultry vaccine development.

journal_name

Vaccine

journal_title

Vaccine

authors

Zhang-Barber L,Turner AK,Barrow PA

doi

10.1016/s0264-410x(99)00060-2

subject

Has Abstract

pub_date

1999-06-04 00:00:00

pages

2538-45

issue

20-21

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(99)00060-2

journal_volume

17

pub_type

杂志文章,评审

相关文献

VACCINE文献大全
  • Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

    abstract：BACKGROUND:Previous studies have demonstrated a correlation between Clostridium difficile anti-toxin A serum antibodies and protection against symptomatic disease and recurrence. METHODS:A neutralizing monoclonal antibody to C. difficile toxin A (CDA1) developed by MBL and Medarex, Inc. was studied in a phase II, rand...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2009.10.144

    authors： Leav BA,Blair B,Leney M,Knauber M,Reilly C,Lowy I,Gerding DN,Kelly CP,Katchar K,Baxter R,Ambrosino D,Molrine D

    更新日期：2010-01-22 00:00:00

  • Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation.

    abstract：:Recently, it was discovered that sialic acid residues on group B streptococcal (GBS) capsular polysaccharides (CPS) are O-acetylated. Since GBS vaccine development has focused on de-O-acetylated CPS, it became germane to investigate the influence of de-O-acetylated GBS vaccine formulations on functional activity of se...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.05.039

    authors： Pannaraj PS,Edwards MS,Ewing KT,Lewis AL,Rench MA,Baker CJ

    更新日期：2009-07-16 00:00:00

  • Novel modifications to the C-terminus of LTB that facilitate site-directed chemical coupling of antigens and the development of LTB as a carrier for mucosal vaccines.

    abstract：:To facilitate site-directed chemical coupling of antigens to the heat labile enterotoxin B subunit of Escherichia coli (LTB), a series of genetically modified fusion proteins of LTB were constructed. The LTB fusion proteins had modified versions of a short (14 amino acid) spacer epitope called the Pk tag attached at t...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00375-2

    authors： O'Dowd AM,Botting CH,Precious B,Shawcross R,Randall RE

    更新日期：1999-03-17 00:00:00

  • V-1 Immunitor: oral therapeutic AIDS vaccine with prophylactic potential.

    abstract：:V-1 Immunitor (V1) is a therapeutic vaccine comprising pooled HIV antigens formulated into an oral pill. Recent V1 studies demonstrated body weight gain, increase in CD4 and CD8 cells, decrease in viral load, and improved survival of end-stage AIDS patients. The potential of V1 as a prophylactic vaccine has been evalu...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0264-410x(02)00570-4

    authors： Jirathitikal V,Sooksathan P,Metadilogkul O,Bourinbaiar AS

    更新日期：2003-01-30 00:00:00

  • Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection.

    abstract：:Prior to routine immunisation, Haemophilus influenzae serotype b (Hib) was a major cause of serious bacterial infections, particularly in young children. In the United Kingdom, introduction of the Hib conjugate vaccine into the national childhood immunisation schedule has led to a sustained decline in invasive Hib dis...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.08.010

    authors： Townsend K,Ladhani SN,Findlow H,Borrow R

    更新日期：2014-09-29 00:00:00

  • Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014.

    abstract：:Hepatitis B infections are responsible for more than 300 thousand deaths per year in the Western Pacific Region. Because of this high burden, the countries and areas of the Region established a goal of reducing hepatitis B chronic infection prevalence among children to less than 1% by 2017. This study was conducted to...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2016.03.060

    authors： Wiesen E,Diorditsa S,Li X

    更新日期：2016-05-27 00:00:00

  • Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis.

    abstract：:In this review, published peer-reviewed preclinical studies using prime-boost tuberculosis (TB) vaccine regimens in animal challenge models for tuberculosis have been evaluated. These studies have been divided into groups that describe prime-boost vaccine combinations that performed better than, equivalent to, or wors...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2012.02.036

    authors： Brennan MJ,Clagett B,Fitzgerald H,Chen V,Williams A,Izzo AA,Barker LF

    更新日期：2012-04-16 00:00:00

  • Seroprevalence of mumps in an epidemic period in Medellín, Colombia.

    abstract：OBJECTIVE:We related seroprevalence and outbreaks data in order to identify factors that could explain the occurrence of outbreaks despite high vaccination coverage in Medellín Colombia. METHODS:Samples from a population seroprevalence data obtained in 2009 in a random survey were analyzed. IgG levels were determined ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.08.088

    authors： Santacruz-Sanmartín E,Hincapié-Palacio D,Ospina MC,Perez-Toro O,Bernal-Restrepo LM,Buitrago-Giraldo S,Lenis-Ballesteros V,Díaz FJ

    更新日期：2015-10-13 00:00:00

  • Effectiveness of the monovalent rotavirus vaccine in Colombia: a case-control study.

    abstract：OBJECTIVE:To assess the effectiveness of the monovalent rotavirus vaccine (RV1) to prevent rotavirus diarrhea admissions to emergency departments (ED) in Colombia. METHODS:A multicenter case-control study was carried out in six Colombian cities from 2011 to January, 2013. Cases were laboratory confirmed rotavirus diar...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.vaccine.2014.03.064

    authors： Cotes-Cantillo K,Paternina-Caicedo A,Coronell-Rodríguez W,Alvis-Guzmán N,Parashar UD,Patel M,De la Hoz-Restrepo F

    更新日期：2014-05-23 00:00:00

  • Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity.

    abstract：:A catch-up campaign targeting children aged 8-16 years using measles-rubella (MR) vaccine was conducted during 2001 in Korea. To evaluate the impact of the campaign and assess mumps immunity, human IgG antibodies were detected using ELISA for measles (5826 samples) and mumps (5890 samples) in a national sample of oppo...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.vaccine.2004.07.030

    authors： Kim SS,Han HW,Go U,Chung HW

    更新日期：2004-12-02 00:00:00

  • Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.

    abstract：:Human papillomavirus type 16 (HPV16)-transformed mouse TC-1 cells are extensively used in the evaluation of efficacy of experimental vaccines against tumours induced by HPVs. As these cells strongly express MHC class I molecules and downregulation of MHC class I surface expression is one of the important mechanisms th...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00519-4

    authors： Smahel M,Síma P,Ludvíková V,Marinov I,Pokorná D,Vonka V

    更新日期：2003-03-07 00:00:00

  • Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein.

    abstract：:Sera were taken over a 5 year period from Gambian children vaccinated in 1983, when aged 1-4 years, with A + C meningococcal capsular polysaccharide, ELISA tests were devised to determine the concentrations of immunoglobulin A, G and M reacting with A polysaccharide and of IgG reacting with Opc protein, IgA1 protease ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(96)00138-7

    authors： Thiesen B,Greenwood B,Brieske N,Achtman M

    更新日期：1997-02-01 00:00:00

  • Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: A desk review of global data sources.

    abstract：INTRODUCTION:The strategy to Eliminate Yellow Fever Epidemics (EYE) is a global initiative that includes all countries with risk of yellow fever (YF) virus transmission. Of these, 40 countries (27 in Africa and 13 in the Americas) are considered high-risk and targeted for interventions to increase coverage of YF vaccin...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.06.063

    authors： Adrien N,Hyde TB,Gacic-Dobo M,Hombach J,Krishnaswamy A,Lambach P

    更新日期：2019-07-26 00:00:00

  • Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.

    abstract：BACKGROUND:Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the searc...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2012.04.007

    authors： Vardas E,Stanescu I,Leinonen M,Ellefsen K,Pantaleo G,Valtavaara M,Ustav M,Reijonen K

    更新日期：2012-06-08 00:00:00

  • Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?

    abstract：:The continued use of oral polio vaccine (OPV) poses a threat to polio virus eradication. Stopping all polio vaccination in the post-certification era is no longer considered to be a practical option. Policy makers agree that OPV use must stop immediately after certification. Therefore, the pragmatic alternative is for...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.02.008

    authors： Khan MM

    更新日期：2008-04-07 00:00:00

  • Noninvasive vaccination: from the perspective of sonoporation.

    abstract：:Previous noninvasive vaccine submission approaches including respiratory tract-based methods are limited to specific pathogens. Recent developments on ultrasound biology suggest that ultrasound-mediated molecule submission (sonoporation) could be an effective noninvasive approach for gene therapy as well as drug submi...

    journal_title：Vaccine

    pub_type： 信件

    doi：10.1016/j.vaccine.2008.04.049

    authors： Yuan TF

    更新日期：2008-08-05 00:00:00

  • Observational study of vaccine effectiveness 20 years after the introduction of universal hepatitis B vaccination in Tunisia.

    abstract：OBJECTIVES:The objectives of this study were to estimate the national prevalence of hepatitis B infection in Tunisia using data from a nationwide survey, to compare results with those obtained in 1996 survey and to evaluate the impact of vaccination twenty years after its introduction. METHODS:A National household-bas...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.08.038

    authors： Ben Hadj M,Bouguerra H,Saffar F,Chelly S,Hechaichi A,Talmoudi K,Bahrini A,Chouki T,Hazgui O,Hannachi N,Letaief H,Bellali H,Bahri O,Ben-Alaya-Bouafif N

    更新日期：2018-09-18 00:00:00

  • Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.

    abstract：:Immune responses to poorly immunogenic antigens, such as polysaccharides, can be enhanced by conjugation to carriers. Our previous studies indicate that conjugation to Vi polysaccharide of Salmonella Typhi may also enhance immunogenicity of some protein carriers. We therefore explored the possibility of generating a b...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.04.035

    authors： An SJ,Scaria PV,Chen B,Barnafo E,Muratova O,Anderson C,Lambert L,Chae MH,Yang JS,Duffy PE

    更新日期：2018-05-17 00:00:00

  • Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.

    abstract：:The ability to elicit humoral and cell-mediated immune (CMI) responses from DNA immunization by combinational use of codon optimization and C3d component of complement was evaluated in this study. DNA vaccines that express either the wild type or the codon optimized gp120 gene coding for the envelope (Env) glycoprotei...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2003.09.054

    authors： Liu F,Mboudjeka I,Shen S,Chou TH,Wang S,Ross TM,Lu S

    更新日期：2004-04-16 00:00:00

  • The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation.

    abstract：:We investigated the influence of the site of administration of DNA vaccine on the induced immune response. DNA vaccines were administered by electroporation at three different sites: tibial cranial muscle, abdominal skin and ear pinna. Aiming to draw general conclusions about DNA vaccine delivery, we successively used...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.05.005

    authors： Vandermeulen G,Vanvarenberg K,De Beuckelaer A,De Koker S,Lambricht L,Uyttenhove C,Reschner A,Vanderplasschen A,Grooten J,Préat V

    更新日期：2015-06-22 00:00:00

  • Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.

    abstract：:Targeted delivery of vaccine candidates to the gastrointestinal (GI) tract holds potential for mucosal immunization, particularly against mucosal pathogens like the human immunodeficiency virus (HIV). Among the different strategies for achieving targeted release in the GI tract, namely the small intestine, pH sensitiv...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.10.030

    authors： Mercier GT,Nehete PN,Passeri MF,Nehete BN,Weaver EA,Templeton NS,Schluns K,Buchl SS,Sastry KJ,Barry MA

    更新日期：2007-12-17 00:00:00

  • Physicochemical and immunological characterization of recombinant host-protective antigen (VP2) of infectious bursal disease virus.

    abstract：:Small fusions to the N-terminal end of the host-protective antigen (VP2) of infectious bursal disease virus lead to stable expression of VP2 in Escherichia coli and yeast, and reduce the levels of inclusion body formation in E. coli in comparison to VP2 constructs with larger N-terminal fusions. VP2 produced with smal...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(91)90286-f

    authors： Azad AA,McKern NM,Macreadie IG,Failla P,Heine HG,Chapman A,Ward CW,Fahey KJ

    更新日期：1991-10-01 00:00:00

  • Colinear synthesis of an antigen-specific B-cell epitope with a 'promiscuous' tetanus toxin T-cell epitope: a synthetic peptide immunocontraceptive.

    abstract：:Carrier conjugation is commonly used to provide T-cell help for small, linear peptides containing antigen-specific B-cell epitopes. However, carrier conjugation is expensive, variable and often results in adverse side effects if the conjugate is administered repeatedly. To eliminate the need for carrier conjugation, w...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(97)00105-9

    authors： O'Hern PA,Liang ZG,Bambra CS,Goldberg E

    更新日期：1997-11-01 00:00:00

  • Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.

    abstract：:Therapeutic immunization of HIV-1-infected individuals with or without anti-retroviral therapy is a new promising disease prevention. To induce a new cytotoxic T(CD8) lymphocyte (CTL) immunity during chronic HIV-1 infection 15 infrequently targeted but conserved HLA-supertype binding CTL epitopes from Gag, Pol, Nef, E...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.07.025

    authors： Fomsgaard A,Karlsson I,Gram G,Schou C,Tang S,Bang P,Kromann I,Andersen P,Andreasen LV

    更新日期：2011-09-16 00:00:00

  • Purification of cell culture-derived influenza A virus via continuous anion exchange chromatography on monoliths.

    abstract：:The continuously increasing demand for potent and safe vaccines and the intensifying economic pressure on health care systems underlines the need for further optimization of vaccine manufacturing. Here, we focus on downstream processing of human influenza vaccines, investigating the purification of serum-free cell cul...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.06.086

    authors： Fischer LM,Wolff MW,Reichl U

    更新日期：2018-05-24 00:00:00

  • Vaccination recommendations for patients with neuromuscular disease.

    abstract：:Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated th...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.09.003

    authors： Esposito S,Bruno C,Berardinelli A,Filosto M,Mongini T,Morandi L,Musumeci O,Pegoraro E,Siciliano G,Tonin P,Marrosu G,Minetti C,Servida M,Fiorillo C,Conforti G,Scapolan S,Ansaldi F,Vianello A,Castaldi S,Principi N,T

    更新日期：2014-10-14 00:00:00

  • Mumps disease in Beijing in the era of two-dose vaccination policy, 2005-2016.

    abstract：BACKGROUND:Since the introduction of mumps-containing vaccines (MuCV) in 1995 in Beijing, two-dose MuCV vaccination policy has been used, with the 1st and 2nd doses given at 18 months and 6 years of age, respectively. METHODS:Mumps epidemiology during 2005-2016 was described using surveillance data. Vaccine effectiven...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.03.074

    authors： Ma R,Lu L,Zhou T,Pan J,Chen M,Pang X

    更新日期：2018-05-03 00:00:00

  • A global perspective of vaccination of healthcare personnel against measles: systematic review.

    abstract：:Measles transmission has been well documented in healthcare facilities. Healthcare personnel who are unvaccinated and who lack other evidence of measles immunity put themselves and their patients at risk for measles. We conducted a systematic literature review of measles vaccination policies and their implementation i...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2013.11.005

    authors： Fiebelkorn AP,Seward JF,Orenstein WA

    更新日期：2014-08-27 00:00:00

  • Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses.

    abstract：:About 10% of health care professionals vaccinated against hepatitis B virus (HBV) fail to develop protective antibodies. We tested the capacity of peripheral blood lymphocytes from 121 health care professionals, including 76 non-responders, to proliferate to four HBV vaccines, examined the proliferating cells' subset,...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.02.046

    authors： Jarrosson L,Kolopp-Sarda MN,Aguilar P,Béné MC,Lepori ML,Vignaud MC,Faure GC,Kohler C

    更新日期：2004-09-09 00:00:00

  • DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.

    abstract：:DNA vaccines contribute to a promising new approach for the generation of cytotoxic T lymphocytes (CTL). DNA vaccines do have several disadvantages, including poor immunogenicity and oncogene expression. We used the natural killer T-cell (NKT) ligand α-galactosylceramide (α-GalCer) as an adjuvant to prime initial DNA ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.08.079

    authors： Kim D,Hung CF,Wu TC,Park YM

    更新日期：2010-10-21 00:00:00